Guggenheim raised the firm’s price target on Structure Therapeutics (GPCR) to $140 from $90 and keeps a Buy rating on the shares. The firm is updating its model to reflect increased confidence in aleniglipron’s ultimate Phase 3 and commercial success after “a strong December” that featured “robust” topline ACCESS Phase 2b data, the Phase 1 start of oral amylin ACCG-2671, and the company being well financed for Phase 3, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics moved to Buy rating at Goldman Sachs
- Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
- Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
- Structure Therapeutics rises 14.1%
- Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating